AMGN vs. GILD, MRNA, REGN, VRTX, ABBV, BMY, JNJ, LLY, MRK, and PFE
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector.
Amgen vs. Its Competitors
Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.
Gilead Sciences has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences has a net margin of 21.86% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Gilead Sciences' return on equity.
Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.7%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays out 62.9% of its earnings in the form of a dividend. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has increased its dividend for 10 consecutive years and Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Gilead Sciences presently has a consensus target price of $117.17, indicating a potential upside of 0.33%. Amgen has a consensus target price of $309.42, indicating a potential upside of 4.70%. Given Amgen's higher possible upside, analysts plainly believe Amgen is more favorable than Gilead Sciences.
In the previous week, Amgen had 8 more articles in the media than Gilead Sciences. MarketBeat recorded 57 mentions for Amgen and 49 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.34 beat Amgen's score of 1.12 indicating that Gilead Sciences is being referred to more favorably in the media.
83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.7% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Amgen beats Gilead Sciences on 11 of the 20 factors compared between the two stocks.
Get Amgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:AMGN) was last updated on 10/8/2025 by MarketBeat.com Staff
